Where the cuts hit in 2009.
Of the dozens of drug companies worldwide that downsized this year, Pfizer has the dubious distinction of having made the most lay-offs. According to a top ten list compiled by newsletter FiercePharma in Washington DC, Pfizer slashed 19,500 jobs, partly as a consequence of its US$68-billion acquisition of Wyeth. Merck, which purchased Schering-Plough for $41 billion, came second with 16,000 lay-offs. Cost-cutting prompted Johnson & Johnson, in third place, and AstraZeneca, in fourth, to shed 8,900 and 7,400 jobs, respectively. GlaxoSmithKline cut 6,000 and Eli Lilly was sixth with 5,500.
Related links
Related links
Related links in Nature Research
Related external links
Rights and permissions
About this article
Cite this article
Pharma job losses ranked. Nature 462, 1085 (2009). https://doi.org/10.1038/nj7276-1085d
Published:
Issue Date:
DOI: https://doi.org/10.1038/nj7276-1085d